CircFOXK2 enhances tumorigenesis and immune evasion in non-small cell lung cancer by miR-485-5p/PD-L1 axis

被引:10
作者
Zhang, Nan [1 ]
Fan, Jian [1 ]
Deng, Zhiping [1 ]
机构
[1] Zigong First Peoples Hosp, Dept Pulm & Crit Care Med, 42 Shangyihao 1st Branch Rd, Zigong 643000, Peoples R China
关键词
circFOXK2; miR-485-5p; non-small cell lung cancer; PD-L1; PD-L1; EXPRESSION; BREAST-CANCER; GENE;
D O I
10.1097/CAD.0000000000001287
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Circular RNAs (circRNAs) serve a key role in lots of cancers. The outcomes of upregulated circular RNA forkhead box K2 (circFOXK2) on non-small cell lung cancer (NSCLC) persisted uncertainly. In this study, the role of circFOXK2 in NSCLC was inspected. Methods The abundances of circFOXK2, microRNA-485-5p (miR-485-5p) and programmed cell death ligand-1 (PD-L1) were confirmed by quantitative real-time PCR and western blot. Cell counting kit-8 (CCK-8) assay and clonogenic assay were accomplished to conclude the proliferation of NSCLC cells. Wound healing and transwell assays were implemented to evaluate cell migration and invasion. Lactate dehydrogenase (LDH) cytotoxicity assay was enforced to quantify the cytotoxicity of CD8(+) T cells. Flow cytometry assay was employed to detect apoptosis. Besides, the mice experiments were utilized for in vivo tumorigenesis analysis. Dual-luciferase reporter assay was carried out to reveal the associations between miR-485-5p and circFOXK2 or PD-L1. Results CircFOXK2 and PD-L1 levels were augmented in NSCLC. CircFOXK2 targeted miR-485-5p, which could bind to PD-L1. CircFOXK2 served a key role in NSCLC tumorigenesis and cytotoxicity of CD8+ T cells. MiR-485-5p inhibition or PD-L1 overexpression abolished the inhibitory effects of circFOXK2 lack on NSCLC tumorigenesis and cytotoxicity of CD8+ T cells. Conclusion CircFOXK2 sponged miR-485-5p to stimulate PD-L1 and expedited NSCLC development.
引用
收藏
页码:437 / 447
页数:11
相关论文
共 42 条
  • [1] MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004)
    Bartel, David P.
    [J]. CELL, 2007, 131 (04) : 11 - 29
  • [2] The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
    Cai, Jiajing
    Wang, Dongsheng
    Zhang, Guoyuan
    Guo, Xiaolan
    [J]. ONCOTARGETS AND THERAPY, 2019, 12 : 8437 - 8445
  • [3] CIRCULAR TRANSCRIPTS OF THE TESTIS-DETERMINING GENE SRY IN ADULT-MOUSE TESTIS
    CAPEL, B
    SWAIN, A
    NICOLIS, S
    HACKER, A
    WALTER, M
    KOOPMAN, P
    GOODFELLOW, P
    LOVELLBADGE, R
    [J]. CELL, 1993, 73 (05) : 1019 - 1030
  • [4] MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions
    Catalanotto, Caterina
    Cogoni, Carlo
    Zardo, Giuseppe
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (10):
  • [5] Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
    Chan, Bryan A.
    Hughes, Brett G. M.
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2015, 4 (01) : 36 - 54
  • [6] Circular RNA 100146 functions as an oncogene through direct binding to miR-361-3p and miR-615-5p in non-small cell lung cancer
    Chen, Lijian
    Nan, Aruo
    Zhang, Nan
    Jia, Yangyang
    Li, Xin
    Ling, Yihui
    Dai, Jiabin
    Zhang, Shaozhu
    Yang, Qiaoyuan
    Yi, Yanni
    Jiang, Yiguo
    [J]. MOLECULAR CANCER, 2019, 18 (1)
  • [7] miRNA-148a serves as a prognostic factor and suppresses migration and invasion through Wnt1 in non-small cell lung cancer
    Chen, Yong
    Min, Lingfeng
    Ren, Chuanli
    Xu, Xingxiang
    Yang, Jianqi
    Sun, Xinchen
    Wang, Tao
    Wang, Fang
    Sun, Changjiang
    Zhang, Xizhi
    [J]. PLOS ONE, 2017, 12 (02):
  • [8] SNHG11 contributes to NSCLC cell growth and migration by targeting miR-485-5p/BSG axis
    Cheng, Ruirui
    Lu, Xinhua
    Xu, Chenyang
    Zhang, Furui
    Zhang, Guojun
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2020, 128
  • [9] Chi DC, 2020, J BUON, V25, P1423
  • [10] Understanding PD-L1 Testing in Breast Cancer: A Practical Approach
    Erber, Ramona
    Hartmann, Arndt
    [J]. BREAST CARE, 2020, 15 (05) : 481 - 490